| Literature DB >> 30038979 |
S J Braak1, Mjl Strijen van2, E Meijer2, Jpm Heesewijk van2, WPThM Mali3.
Abstract
OBJECTIVES: Quantitative analysis of operator dose in cone-beam computed tomography guidance (CBCT-guidance) and the effect of protective shielding.Entities:
Keywords: cone beam CT; effective dose; needle intervention; radiation shielding; staff
Year: 2016 PMID: 30038979 PMCID: PMC5854453 DOI: 10.5334/jbr-btr.816
Source DB: PubMed Journal: J Belg Soc Radiol ISSN: 2514-8281 Impact factor: 1.894
Figure 1Cone-Beam CT-guidance procedure on a 59-years-old male with a suspected mass in the hilum of the right kidney. Histopathological result revealed a small cell neuroendocrine carcinoma for which this patient underwent a nephrectomy. (A) Entrypoint (EP) geometric configuration of the C-arm, looking ‘down-the-barrel’ (with arrow). (B) shows the common geometric configuration of the C-arm in the Progress view (PV). This clearly shows the close position of the operator to the radiation beam.
Figure 2The disposable lead drape armor (Pb equivalent of 0.25 mm) as positioned during the model measurement with a Rando-phantom®.
Figure 3The rotation (A) and angulation (B) of the C-arm used during the model measurements of scatter radiation for the operator. Dose measurement was performed in every combination of rotation projections between -120 degrees to +120 degrees at an interval of 30 degrees and in every angulation projection with an interval of 20 degrees in a range between -40 degrees to +40 degrees.
Overview of the characteristics used for the model and during the clinical cases.
| Thorax | Abdomen | total | ||
|---|---|---|---|---|
|
| ||||
| Scatter radiation model | N | 47 | 66 | 113 |
| Sex | 19 women / 19 men | 28 women / 47 men | 47 women/ 66 abdomen | |
| Mean age (y) | 62.1 (range 24–85) | 63.9 (range 32–83) | 63.3 (range 24–85) | |
| Mean target size (mm) | 31.0 (95% CI 24.3–37.6) | 25.1 (95% CI 20.1–30.1) | 27.8 (95% CI 23.8–31.8) | |
| Mean BMI (kg/m2) | 23.9 (95% CI 23.5–24.3) | 23.9 (95% CI 23.5–24.3) | 23.9 (95% CI 23.8–24.0) | |
| Clinical cases | N | 17 | 20 | 37 |
| Sex | 5 women / 12 men | 8 women / 12 men | 13 women / 24 men | |
| Mean age (y) | 67.3 (range 35–83) | 62.6 (range 35–83) | 64.7 (range 35–83) | |
| Mean length size (mm) | 23.7 (95% CI 19.8–30.1) | 22.9 (95% CI 17.7–27.5) | 23.3 (95% CI 20.5–27.2) | |
| Mean BMI (kg/m2) | 24.4 (95% CI 23.4–25.5) | 24.0 (95% CI 22.9–25.0) | 24.2 (95% CI 23.5–24.9) | |
Overview of the data in entrypoint view, progress view and in total. Data is based on the clinical setting and used for the scatter radiation model.
| Entrypoint | Progress View | Total | ||||
|---|---|---|---|---|---|---|
| Thorax | Abdomen | Thorax | Abdomen | Thorax | Abdomen | |
|
| ||||||
| Fluoroscopy time (s); median (95% CI) | 74.4 (64.6–84.3) | 68.3 (62.4–74.1) | 137.9 (124.8–150.9) | 111.4 (103.9–118.8) | 212.3 (192.7–231.9) | 179.7 (168.7–190.6) |
| kV; median (95% CI) | 91.9 (90.4–93.3) | 98.6 (97.2–100.1) | 103.3 (101.2–105.3) | 117.7 (117.0–118.4) | ||
| mAs; median (95% CI) | 13.5 (13.3–13.7) | 14.7 (14.5–14.8) | 14.9 (14.6–15.1) | 15.4 (15.3–15.6) | ||
| Field Diameter (cm) ; median (95% CI) | 27.7 (25.3–30.1) | 28.0 (26.0–30.0) | 27.7 (25.6–29.7) | 31.1 (29.5–32.8) | ||
| Angulation; median (95% CI) | –3° (–8°–+2°) | 11° (7°–15.0°) | 0° (–0°–0°) | 0° (0°–0°) | ||
| Rotation; median (95% CI) | –4° (–12°–+5°) | –4.0° (–10°–+2°) | –22° (–44°–1°) | –25° (–45°– –6°) | ||
| Dose Hand (µSv); median (95% CI) | 10.7 (8.2–13.1) | 17.9 (13.2–22.6) | 23.5 (17.4–29.7) | 36.7 (30.9–42.6) | 34.2 (26.9–41.5) | 54.6 (46.9–62.4) |
| Dose Thyroid region (µSv); median (95% CI) | 68.6 (–3.4–140.5) | 42.6 (9.1–76.1) | 13.8 (9.2–18.4) | 23.6 (17.7–29.5) | 83.2 (11.1–155.3) | 66.2 (31.4–100.9) |
| Dose Gonads region (µSv); median (95% CI) | 17.8 (11.1–24.4) | 20.8 (17.2–24.4) | 16.1 (11.6–20.7) | 26.4 (20.9–32.0) | 34.3 (26.0–42.7) | 47.2 (39.9–54.5) |
| Dose Thyroid Shielding (µSv); median (95% CI) | 1.7 (–0.1–3.4) | 0.7 (0.2–1.2) | 0.5 (0.3–0.6) | 1.0 (0.7–1.3) | 2.2 (0.4–3.9) | 1.7 (1.1–2.3) |
| Dose Gonads Shielding (µSv); median (95% CI) | 1.3 (0.9–1.7) | 1.5 (1.2–1.8) | 1.3 (0.9–1.7) | 2.1 (1.6–2.6) | 2.6 (2.0–3.2) | 3.6 (2.9–4.2) |
| Dose Hand Drape (µSv); median (95% CI) | 3.3 (2.4–4.2) | 7.1 (4.1–10.0) | 4.6 (3.5––5.8) | 10.5 (6.3–14.8) | 7.9 (6.1–9.8) | 17.6 (11.9–23.4) |
| Dose Thyroid Drape (µSv); median (95% CI) | 94.7 (–22.1–211.6) | 76.8 (14.4–139.3) | 16.7 (8.7–24.7) | 21.8 (18.3–25.3) | 111.4 (–5.9–228.7) | 98.6 (35–161.4) |
| Dose Gonads Drape (µSv); median (95% CI) | 33.8 (19.2–48.5) | 34.3 (26.9–41.8) | 26.4 (9.3–33.5) | 37.8 (29.6–46.0) | 60.2 (43.9–76.5) | 72.1 (59.2–85.0) |
| Dose Thyroid Both (µSv); median (95% CI) | 0.06 (0.00–0.14) | 0.05 (0.03–0.08) | 0.02 (0.01–0.02) | 0.13 (0.05–0.21) | 0.08 (0.01–0.16) | 0.18 (0.08–0.28) |
| Dose Gonads Both (µSv); median (95% CI) | 0.06 (0.00–0.13) | 0.05 (0.02–0.08) | 0.18 (0.12–0.25) | 0.40 (0.24–0.56) | 0.37 (0.28–0.46) | 0.84 (0.55–1.13) |
Thorax group.
| Couch/Ceiling Shielding | Lead drape Shielding | Couch/Ceiling and Lead drape Shielding | ||
|---|---|---|---|---|
|
| ||||
| Hand | Entrypoint | No difference | –68.9% | No difference compared to lead drape shielding |
| Progress View | –80.4% | |||
| Total | –76.8% | |||
| Thyroid region | Entrypoint | –97.5% | +38.4% | –99.8% |
| Progress View | –96.6% | +13.8% | –99.5% | |
| Total | –97.4% | +33.9%* | –99.7% | |
| Gonad region | Entrypoint | –93.2% | +90.3% | –97.9% |
| Progress View | –91.6% | +59.3% | –98.4% | |
| Total | –92.4% | +75.3% | –98.2% | |
Percentages of dose difference compared to the setting without any radiation shielding in the scatter radiation model. All percentages represent significant (p<0.05) changes expect the one marked with an asterix (*; p=0.31).
Abdominal group.
| Couch/Ceiling Shielding | Lead drape Shielding | Couch/Ceiling and Lead drape Shielding | ||
|---|---|---|---|---|
|
| ||||
| Hand | Entrypoint | No difference | –60.4% | No difference compared to lead drape shielding |
| Progress View | –71.3% | |||
| Total | –67.8% | |||
| Thyroid region | Entrypoint | –98.4% | +80.5% | –99.9% |
| Progress View | –95.8% | –7.7%* | –99.8% | |
| Total | –97.4% | +49.0% | –99.8% | |
| Gonad region | Entrypoint | –92.8% | +65.2% | –98.9% |
| Progress View | –92.0% | +42.9% | –98.7% | |
| Total | –92.4% | +52.8% | –98.9% | |
Percentages of dose difference compared to the setting without any radiation shielding in the scatter radiation model. All percentages represent significant (p<0.05) changes expect the one marked with an asterix (*; p=0.43).